1) Treating both hypertension and dyslipidemia together provides greater reduction in cardiovascular events than treating either condition alone, as shown in the ASCOT trial. 2) While lowering blood pressure and lipids significantly reduces cardiovascular risk as demonstrated in multiple clinical trials, current treatment and control rates globally remain inadequate. 3) Concerns about statin safety have been overstated and discontinuing statin therapy has been linked to increased cardiovascular events and mortality.